Overall Technical outlook

Price Summary

On 2025-12-10, Piramal Pharma Limited's stock opened at 173.42, spiked to 174.45, declined to 170.1, and closed -1.4% down at 170.99, with 1935171 shares traded.
The peak price for the stock in the past 52 weeks is 266.25, with the lowest price being 170.99.
The future price of PPLPHARMA is projected to range from 195.0 to 310.0, with an average expected price of 244.33333, according to 9 analysts.

Technicals


Aroon: Aroon's bearish trend remains strong, with Aroon Down still at the 100 level. This suggests ongoing downward pressure. However, this trend should be further explored using additional indicators to gain a clearer understanding of its long-term significance.
PPLPHARMA aroon 2c02ec
Aroon chart for Piramal Pharma Limited


Bol. Bands: The price has fallen below the lower Bollinger Band, suggesting that the market might be experiencing oversold conditions. This move reflects increased selling pressure, driving prices to a significant low. The breach could either indicate a continuation of the downtrend or a possible reversal if traders start to see this as a buying opportunity at these depressed levels.
PPLPHARMA bbands 2c02ec
Bolinger Bands chart for Piramal Pharma Limited


Parabolic SAR: The PSAR remains in a bearish mode, setting a strong resistance level that could impede any upward trends. This resistance indicates that the market may struggle to break higher, reflecting ongoing bearish sentiment for PPLPHARMA.
PPLPHARMA psar 2c02ec
Parabolic Stop and Reverse chart for Piramal Pharma Limited


Stochastic: The Stochastic K-line's drop below the D-line and under 20 points to a mildly bearish market condition for PPLPHARMA. While this indicates some bearish sentiment, it's not a strong signal. Investors should be aware of this potential shift and look for additional confirmation before making decisions.
PPLPHARMA stoch 2c02ec
Stochastic chart for Piramal Pharma Limited


Tripple Moving Agerage: The 20-50-100 period moving averages are positioned for a bullish trend, but the slopes of the faster averages hint at a possible trend reversal. While the overall outlook remains positive, the weakening momentum in the shorter-term averages suggests that the current trend might not hold for long.
PPLPHARMA trippleSMA 2c02ec
Tripple SMA chart for Piramal Pharma Limited


A comprehensive approach to analyzing a company requires considering both its technical and fundamental aspects. The company's fundamentals, such as its earnings, growth prospects, and financial health, provide a strong foundation for understanding technical indicators. Additionally, examining the industry it operates in helps contextualize the company's position within the broader market. By integrating these factors, one can gain more valuable insights into the company's stock performance and potential investment opportunities.